Reductions in key non-invasive tests (NITs) of liver inflammation and fibrosis support previously demonstrated fibrosis improvements across compensated.
Phase 3 data presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases demonstrated the safety and efficacy of seladelpar in patients with primary biliary cholangitis through 12 months of treatment.
Reductions in key non-invasive tests of liver inflammation and fibrosis support previously demonstrated fibrosis improvements across compensated cirrhotic patients at week 24 A.
Results presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases highlighted an association between food insecurity and low household income with the risk of NAFLD in adolescents.
New pooled phase 3 and extension trial data show odevixibat continues to improve disease management and itch reduction in children with Alagille syndrome.